MONISTAT 3
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT 3 (MONISTAT 3).
Miconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Hepatic via CYP3A4; minimal systemic absorption after intravaginal administration (<1.4%). |
| Excretion | Primarily fecal (97%) via biliary excretion; renal excretion of unchanged drug is negligible (<1%). |
| Half-life | Terminal elimination half-life is approximately 30 hours after topical vaginal application; prolonged in hepatic impairment. |
| Protein binding | Approximately 90-95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution is approximately 2.8 L/kg after IV administration (for systemic formulation), indicating extensive tissue penetration; vaginal absorption minimal, with Vd not clinically relevant for topical use. |
| Bioavailability | Topical vaginal: approximately 5-10% systemically absorbed; oral: minimally absorbed (<1%) due to poor solubility. |
| Onset of Action | Clinical relief of symptoms (itching, discharge) typically begins within 24 hours of first dose. |
| Duration of Action | Therapeutic effect persists for up to 3 days after completion of 3-day regimen; full eradication may require 7 days for non-responsive cases. |
| Molecular Weight | 416.13 |
One vaginal suppository (200 mg miconazole nitrate) intravaginally at bedtime for 3 consecutive days; or one applicatorful (5 g) of 4% vaginal cream intravaginally at bedtime for 7 days.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment; data limited for severe impairment (eGFR <30 mL/min). |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); use with caution in severe impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | Children ≥12 years of age: same as adult dosing (200 mg vaginal suppository at bedtime for 3 days or 4% cream for 7 days). Children <12 years: not recommended; safety and efficacy not established. |
| Geriatric use | No specific dosage adjustment required; use same as adult dosing. Absorption does not significantly differ in elderly patients. |
| 1st trimester | Topical miconazole is considered generally safe in the first trimester, as systemic absorption is minimal. However, use only if clearly indicated and under medical supervision. |
| 2nd trimester | Topical miconazole is considered safe in the second trimester; minimal systemic absorption poses low risk. |
| 3rd trimester | Topical miconazole is considered safe in the third trimester; avoid use near term due to theoretical risk of premature labor from prostaglandin release (though not substantiated). |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT 3 (MONISTAT 3).
| Placental transfer | Negligible systemic absorption limits placental transfer; no significant fetal exposure expected with topical use. |
| Breastfeeding | Minimal systemic absorption after topical application makes transfer into breast milk negligible. Generally considered compatible with breastfeeding. Avoid application to breast area to prevent infant ingestion. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to miconazole or any component of the formulation
| Precautions | Hepatic impairment; use during pregnancy (Category C) only if clearly needed; possible hypersensitivity reactions including anaphylaxis; discontinue if irritation or sensitization occurs; may interact with warfarin (enhances anticoagulant effect). |
| Food/Dietary | No known significant food interactions. Avoid alcohol if taking oral miconazole (not relevant here); for vaginal suppository, no dietary restrictions. Maintain adequate hydration. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Miconazole nitrate (MONISTAT 3) is pregnancy category C. In animal studies, miconazole has shown embryotoxicity and fetotoxicity at high doses, but no well-controlled studies exist in pregnant women. Systemic absorption from vaginal use is minimal, but first-trimester use is generally avoided unless benefit outweighs risk. Second and third trimester use for localized infections is considered low risk due to limited systemic exposure. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care. However, if symptoms persist or infection recurs, confirm diagnosis and consider alternative therapy. |
| Fertility Effects | There are no known adverse effects of miconazole on female or male fertility. Animal studies show no impairment of fertility at clinically relevant doses. |
| MONISTAT 3 (miconazole nitrate 200 mg vaginal suppository) is indicated for vulvovaginal candidiasis. For uncomplicated infections, a 3-day regimen is standard; consider 7-day course for severe or recurrent cases. Avoid use during menstruation; treat after menses. Miconazole may weaken latex condoms and diaphragms; advise alternate contraception for 3 days post-treatment. |
| Patient Advice | Insert one suppository vaginally at bedtime for 3 consecutive nights. · Wash hands before and after insertion; use the provided applicator as directed. · Do not use if you have abdominal pain, fever, chills, nausea, or foul-smelling discharge; seek medical attention. · May cause mild burning or irritation; discontinue if severe or allergic reaction occurs. · Refrain from sexual intercourse during treatment; miconazole can damage latex condoms and diaphragms. · Complete full course even if symptoms improve; if no relief in 3 days, consult prescriber. |